Decentralized science (DeSci) protocols are at a developmental stage similar to decentralized finance (DeFi) in 2019, according to Mechanism Capital's Andrew Kang. He describes DeSci as raw and experimental but imbued with substantial potential. Kang suggests that DeSci protocols, like early DeFi projects, will likely undergo significant changes in their models and products. He highlights several promising DeSci projects, including BIO Protocol, which allows users to co-own future medicines; Pump Science, which facilitates trading tokens related to longevity medicines; and GLP1, which focuses on weight management. DeSci, emerging from the COVID-19 pandemic, leverages blockchain to enhance community-driven scientific research while aiming to counter institutional influences like big pharma. The DeSci sector has a current market cap of $1.2 billion, spearheaded by OriginTrail, followed by Rifampicin and VitaDAO. This growth aligns with increasing data accessibility in healthcare, particularly amidst rising cyber threats to healthcare information.

Source 🔗